A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy.
BMC Neurol
; 24(1): 214, 2024 Jun 24.
Article
em En
| MEDLINE
| ID: mdl-38914929
ABSTRACT
BACKGROUND:
Chronic migraine (CM) is the most severe and burdensome subtype of migraine. Fremanezumab is a monoclonal antibody that targets the calcitonin gene-related peptide pathway as a migraine preventive therapy. This study aimed to conduct a cost-effectiveness analysis of fremanezumab from a societal perspective in the Netherlands, using a Markov cohort simulation model.METHODS:
The base-case cost-effectiveness analysis adhered to the Netherlands Authority guidelines. Fremanezumab was compared with best supportive care (BSC; acute migraine treatment only) in patients with CM and an inadequate response to topiramate or valproate and onabotulinumtoxinA (Dutch patient group [DPG]). A supportive analysis was conducted in the broader group of CM patients with prior inadequate response to 2-4 different classes of migraine preventive treatments. One-way sensitivity, probabilistic sensitivity, and scenario analyses were conducted.RESULTS:
Over a lifetime horizon, fremanezumab is cost saving compared with BSC in the DPG (saving of 2514 per patient) and led to an increase of 1.45 quality-adjusted life-years (QALYs). In the broader supportive analysis, fremanezumab was cost effective compared with BSC, with an incremental cost-effectiveness ratio of 2547/QALY gained. Fremanezumab remained cost effective in all sensitivity and scenario analyses.CONCLUSION:
In comparison to BSC, fremanezumab is cost saving in the DPG and cost effective in the broader population.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Análise Custo-Benefício
/
Transtornos de Enxaqueca
/
Anticorpos Monoclonais
País/Região como assunto:
Europa
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Holanda